What is Agilvax?
Agilvax operates at the intersection of advanced biotechnology and tumor biology, specializing in the engineering of targeted antibodies designed to combat metastatic cancer. The company distinguishes itself through a systematic approach to drug discovery, prioritizing high-precision interventions that address the underlying mechanisms of tumor progression. By fostering deep-rooted collaborations with leading academic institutions, Agilvax facilitates the rapid translation of complex biological insights into actionable clinical candidates. This strategic positioning allows the firm to maintain a robust pipeline of innovative treatment options, aiming to redefine the standard of care for patients facing advanced-stage malignancies. Their commitment to rigorous scientific methodology ensures that each therapeutic candidate is optimized for efficacy and safety prior to entering the clinical trial phase.
How much funding has Agilvax raised?
Agilvax has raised a total of $11.3M across 3 funding rounds:
Series A
$10M
Grant
$1.2M
Debt
$136K
Series A (2020): $10M with participation from Southwest Medical Ventures
Grant (2020): $1.2M led by National Cancer Institute
Debt (2021): $136K supported by PPP
Key Investors in Agilvax
Southwest Medical Ventures
A specialized venture capital firm with a focus on founding and scaling life sciences and healthcare companies since 1992.
National Cancer Institute
A federal agency dedicated to reducing the prevalence of cancer through rigorous research, biological study, and the development of new clinical interventions.
PPP
Public-Private Partnership
What's next for Agilvax?
With the recent influx of capital, Agilvax is poised to enter a pivotal phase of organizational growth and clinical expansion. The strategic roadmap focuses on the maturation of its lead antibody candidates, with a primary objective of achieving key milestones in clinical trial readiness. Management is expected to prioritize the scaling of internal research capabilities and the expansion of its intellectual property portfolio to solidify its market position. Furthermore, the firm will likely leverage its existing institutional partnerships to streamline the regulatory pathway, ensuring that its novel therapies can reach the market with maximum efficiency. As the company moves toward subsequent funding rounds, the focus will remain on demonstrating clinical utility and long-term therapeutic value in the oncology sector.
See full Agilvax company page
